Similarly, the phase II BOLERO‐5 study, which evaluated the efficacy of everolimus combined with exemestane in Chinese postmenopausal ER‐positive/HER2‐negative advanced breast cancer patients, produced results consistent with those of the international multicenter BOLERO‐2 study. The gene discussed is ERBB2; the disease is breast cancer.